The Metabolic Classroom with Dr. Ben Bikman

Episode: Why Alzheimer’s May Be a Metabolic Disease
Date: March 9, 2026
Host: Dr. Ben Bikman (Metabolic Scientist, Professor of Cell Biology)
Podcast: The Metabolic Classroom (by Insulin IQ)

Episode Overview

Dr. Ben Bikman delivers a detailed, practical, and critical mini-lecture about the dominant theories of Alzheimer’s disease. He explains why mounting evidence suggests that Alzheimer’s may fundamentally be a metabolic disorder—specifically, “type 3 diabetes,” or brain-based insulin resistance—rather than a disease driven by brain plaques alone. Dr. Bikman takes listeners through the scientific history, controversies, failures of existing drug treatments, and the potential for new, metabolism-centered approaches to Alzheimer's prevention and mitigation.

Key Discussion Points & Insights

1. Historical Background of Alzheimer’s Disease

• Founding Observations:

  • 1906: Dr. Alois Alzheimer identified hallmark "sticky plaques" (amyloid beta) and "tangled fibers" (tau) in the brain of a patient with profound memory loss.
  • This seeded the plaque-centric theory of Alzheimer’s.
  • [02:55] “That was the birth of what we now call Alzheimer’s disease.”

• The Amyloid Cascade Hypothesis:

  • Emerged in the 1990s, suggesting amyloid plaques were the cause of Alzheimer’s, sparking massive research and drug development investments.

2. Cracks in the Paradigm: Plaques as Cause or Consequence?

• Weak Correlation Between Plaques and Disease:

  • Many with plaques show no cognitive impairment; some with Alzheimer’s have few plaques.
  • [05:25] “The amounts and distribution of a beta deposition are only weakly correlated with the clinical expression of the disease."

• Quote:

  • [05:40] “By age 80, as many as 60% of cognitively normal elderly individuals have detectable amyloid in their brains. That is a fundamental problem. If plaques caused dementia, they should track with dementia. They often don’t.” – Dr. Ben Bikman

• Scientific Fraud and Retractions:

  • A pivotal 2006 Nature paper, foundational for amyloid research, was retracted in 2024 due to data fabrication.
  • Large numbers of related papers were also found to contain doctored data, further destabilizing the “plaque hypothesis.”
  • [07:10] “It was eventually retracted in 2024… Now it is the second most highly cited paper that has ever been retracted.”

3. Failures of Amyloid-Targeting Drugs

• Repeated Clinical Failures:

  • From 2003–2021, no new drugs targeting amyloid plaques provided clinical benefit, despite billions spent and intensive research focus.
  • [09:10] “None showed meaningful cognitive benefits. Billions of dollars, but zero new treatments.”

• Controversies in Drug Approval:

  • Aducanumab’s FDA approval in 2021 was highly controversial and reversed in 2024 due to underwhelming results and concerning side effects (brain swelling, microbleeds).
  • [09:30] “It seems increasingly apparent that clearing plaques does not cure the disease… It doesn’t even stop its progression.”

4. A Metabolic Reframing: Alzheimer’s as “Type 3 Diabetes”

• Introduction to Brain Insulin Resistance:

  • Research led by Dr. Suzanne de la Monte demonstrated that disabling the brain's insulin receptors in rats replicates Alzheimer’s-like changes—plaques, tangles, and cognitive decline.
  • [11:00] “She later coined the term type 3 diabetes to describe Alzheimer’s, a form of diabetes that selectively involves the brain…”

• Insulin’s Role in Brain Health:

  • Insulin in the brain is essential for energy supply, neuronal survival, synaptic plasticity, inhibiting tau tangles, clearing amyloid, and neurotransmitter regulation.
  • [13:00] “When brain insulin signaling fails, you get energy starvation of neurons, a runaway of tau phosphorylation inducing the tangles, and you have impaired amyloid clearance.”

• Core Insight:

  • [15:35] “The full picture of Alzheimer’s pathology could be explained as downstream consequences of impaired insulin signaling in the brain. Nothing more, nothing less.”

5. Epidemiology: Diabetes, Insulin Resistance, and Dementia

• Elevated Risk in Diabetics:

  • Meta-analyses consistently show that diabetes significantly raises the risk—by 56–73%—of Alzheimer’s and other dementias.
  • Longer diabetes duration and higher blood sugar further elevate risk, with early-onset diabetes tripling Alzheimer’s risk.
  • [16:26] “A 2025 meta-analysis... found that those with longer diabetes duration had substantially higher dementia risk.”

• Important Nuance:

  • Not everyone with diabetes develops Alzheimer’s, nor do all Alzheimer’s patients have diabetes. There may be both secondary (systemic) and primary (brain-specific, possibly genetic) insulin resistance.

6. Genetics & APOE4: Connecting Genes and Metabolic Dysfunction

• APOE4 as a Metabolic Risk Factor:

  • The APOE4 allele is a major genetic risk factor for Alzheimer’s; it impairs insulin receptor placement on neuron surfaces, reducing insulin signaling independently of blood insulin.
  • [19:02] “APOE4 may be fundamentally and directly impairing the brain’s insulin signaling system, creating a condition of brain specific insulin resistance with a very clear genetic origin.”

• Quote:

  • [20:44] “The brain starves for energy… Amyloid accumulates because the clearance machinery that depends on insulin signaling has broken.”

7. Alternative Brain Fuel: Ketones and Metabolic Rescue

• Glucose Starvation – Ketone Rescue:

  • The Alzheimer's brain loses capacity to process glucose but retains the ability to utilize ketone bodies for energy—without needing insulin.
  • PET imaging (Cunnane et al.) shows that, while glucose uptake is reduced by up to 32% in Alzheimer’s brains, ketone metabolism remains intact.
  • [25:26] “In mild to moderate Alzheimer’s disease, brain glucose uptake was up to 32% lower… But ketone uptake in metabolism was completely normal.”

• Molecular Evidence:

  • Dr. Bikman’s lab found impaired glucose-burning gene activity in all brain cell types in Alzheimer’s, but near-normal gene activity for ketone metabolism.
  • [28:40] “The molecular machinery for burning glucose was broadly impaired... But ketolytic gene expression was not significantly altered.”

• Dietary Implications:

  • Ketones are only produced with low insulin—during fasting or carbohydrate restriction. High-carb diets keep ketone levels near zero, stranding the Alzheimer’s brain in an energy crisis.

• Clinical Trials & Exogenous Ketones:

  • Early studies show ketone supplementation improves cognitive function, especially in those without APOE4, but benefits all.
  • [30:34] “There is a study finding that at 90 days with patients taking an MCT-based ketogenic compound, patients who achieved ketosis showed significant improvements on cognitive assessments…”

8. Prevention & Hope: Practical Takeaways

• Prevention Decades Before Disease:

  • Metabolic dysfunction associated with Alzheimer’s can be detected decades before symptoms—examples include young women with PCOS (another insulin-resistant state).

• Lifestyle Change is Key:

  • Improving insulin sensitivity (low-carb diet, exercise, weight management) likely provides the best-known prevention strategy.

• APOE4 Consideration:

  • Genetic risk is not destiny, but those with APOE4 should be especially diligent about metabolic health and may benefit most from carbohydrate restriction.

• Quote:

  • [33:42] “We don’t yet have a drug that stops Alzheimer’s, but we may have lifestyle strategies that substantially reduce the risk of ever developing it.”

Notable Quotes & Memorable Moments

• [05:40] “By age 80, as many as 60% of cognitively normal elderly individuals have detectable amyloid… If plaques caused dementia, they should track with dementia. They often don’t.” – Dr. Ben Bikman
• [07:10] “It was eventually retracted in 2024… Now it is the second most highly cited paper that has ever been retracted.”
• [09:30] “It seems increasingly apparent that clearing plaques does not cure the disease… It doesn’t even stop its progression.”
• [15:35] “The full picture of Alzheimer’s pathology could be explained as downstream consequences of impaired insulin signaling in the brain. Nothing more, nothing less.”
• [20:44] “The brain starves for energy… Amyloid accumulates because the clearance machinery that depends on insulin signaling has broken.”
• [25:26] “In mild to moderate Alzheimer’s disease, brain glucose uptake was up to 32% lower… But ketone uptake in metabolism was completely normal.”
• [33:42] “We don’t yet have a drug that stops Alzheimer’s, but we may have lifestyle strategies that substantially reduce the risk of ever developing it.”
• [34:59] “The metabolic theory of Alzheimer’s does something the plaque theory struggled to do. It really tells a complete mechanistic story from cell biology through epidemiology. It connects all the dots and… opens the door for… much more meaningful interventions in the future.”

Key Timestamps of Important Segments

| Time | Segment | |----------|----------------------------------------------| | 02:00 | Historical foundation of Alzheimer’s | | 04:30 | Plaque hypothesis and early skepticism | | 07:00 | Scientific fraud, pivotal retraction | | 09:10 | Drug trial failures and the Aducanumab story | | 11:00 | Introduction of Type 3 Diabetes theory | | 13:00 | Insulin’s roles in healthy brain function | | 15:35 | “Metabolic reframing” summarized | | 16:26 | Epidemiology: diabetes, dementia risk | | 19:00 | APOE4 and impaired insulin signaling | | 25:26 | Glucose vs. ketone PET imaging findings | | 28:40 | Dr. Bikman’s gene expression research | | 30:34 | Clinical results with ketone supplements | | 33:42 | Practical prevention and lifestyle advice | | 34:59 | Closing reflection on shifting paradigms |

Conclusion

Dr. Bikman challenges the mainstream “plaque hypothesis” of Alzheimer’s, pointing to major scientific, clinical, and epidemiological weaknesses, including infamous research fraud. Instead, he lays out a coherent mechanistic argument that Alzheimer’s is, at its core, an issue of brain insulin resistance—a phenomenon sometimes referred to as “type 3 diabetes.”
He emphasizes that this view better fits the molecular and clinical data, opens new therapeutic hopes—especially through dietary change and use of ketones as neural fuel—and empowers listeners and their loved ones to take preventative action, decades before dementia might appear.

“Science advances when honest researchers are willing to follow the data wherever it leads, even when it may be uncomfortable… The metabolic theory of Alzheimer’s opens the door for much more meaningful findings and interventions in the future.”
— Dr. Ben Bikman [34:59]

For more detailed information or to share this episode, visit BenBikman.com or InsulinIQ.com